1. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Opportunities to bridge the technology gap between academia and industry. The view from one pharma

2. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY AstraZeneca Major world wide Pharma Active in more than 100 countries world wide 2008 sales of $31.6 billion >3% increase on 2007 65,000 employees world wide 12,000 staff in R&D >$5 billion invested in R&D 17 principle R&D centers across 8 countries Focus on 6 therapy areas Oncology Cardio Vascular Respiratory and Inflamation Infection Neuroscience Gastrointestinal

3. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Pipeline of NCEs as of Jan 2009 Phase 1 trial 23 small molecules 10 biologicals Phase 2 trials 26 small molecules 5 biologicals Phase 3/ registrations 9 small molecules 1 biological Data from 2008 annual report

4. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Acquisitions and Licensing 35-40 major business development transactions (2008 annual report) Some examples of recent acquisitions Biologicals Cambridge Antibody Technologies MedImmune Infection Arrow Therapeutics Oncology KuDos Pharmaceuticals Licensing 11 of the NCEs currently in clinical trials are partnered products

5. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Links with Academic Institutions Within the UK 2008 started collaboration with Cancer Research UK – Linking an AstraZeneca development compound with the charities Clinical Development Partnership program Royal Marsden NHS foundation trust – accessing imaging technology to study the impact of Recentin on solid tumours Manchester University – strategic alliance to look at imaging biomarkers. In addition there are links through Manchester University to the National Cancer Centre Singapore Newcastle University – linked with Astrazeneca via Cancer Research Technology Ltd and KuDOS to study DNA-PK inhibitors MRC – 4 PhDs BBSRC – AstraZeneca linked with the Babraham Institute Division of Signal Transduction Therapy – University of Dundee

6. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Links with Overseas Academics ICC – Innovation Centre China ($100M investment) University of Washington St Louis – Investigation in to Alzheimer’s Disease to find better ways of diagnosis and treatment Columbia University Medical Center – Identification of new targets and novel therapies for type 2 diabetes and obesity Virginia Tech and Mayo Clinic – licensing agreement for the triple reuptake inhibitor for treatment of depression University of Texas MD Anderson Cancer Center – Studying cancer related pain Clinical studies and alliances with several US cancer institutes including Mass General Hospital, Vanderbilt-Ingram Cancer Center, University of Colorado and National Cancer Institue

7. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Technology Collaborations Silence Therapeutics – novel system for using siRNA molecules to target respiratory disease Cell Signaling Technology – PhosphoScan R – CST generated antibodies to phosphorylated peptides used to IP proteins from cell lysates. These are analysed by LC-MS to monitor changes in the levels of phosphorlyation within the cell during treatment with potential kinase inhibitors Astex Therapeutics – fragment based drug discovery – expertise in NMR screening, crystalography and Isothermal calorimetry

8. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Building a partnership with AstraZeneca Strategic Planning and Business Development (SPBD) Group Main role is to manage in-licensing activities Aligned with therapy areas Also involved with out licensing, spin offs, risk sharing deals Established a Master agreement system for main collaborators Manchester Cancer Research Centre Royal Marsden Hospital NKI-AVL – Netherlands Cancer Institute Strategic Alliances Group Science and Technology Alliances Group Collaborations relating to technology which is applicable across therapy areas Advanced Science and Technology Lab – ASTL

9. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Areas of interest Chemistry New synthetic methodologies Novel lead generation technologies Predictive QSAR methodologies Predictive Biology High Content Screening technologies Novel physiological cell based efficacy screening technologies Target validation methodologies Improved methodologies to predict safety/toxicity In silico simulation In vivo predictive models In vivo imaging Predictive medicine Rapid biomarker analysis techniques Imaging to provide functional measurements of disease activity Knowledge management/informatics Structured searching and text mining Patent informatics

10. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Funding Internal Innovation funding <$1M Should not include capital purchases Aim to identify new and novel technologies to improve our lead generation screening capability Partnerships with charitable organisations and governments BBSRG, MRC etc Corporate funding Direct from research areas – very limited Risk sharing deals AZ contribute with resources and knowledge FTE Lab space Compound libraries Chemistry In vitro/ In vivo testing Share rewards between AZ and academic/biotech

11. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY What can AZ offer Large and ever expanding compound collection 4 HTS centres across the globe supporting 6 therapy areas 2 in UK 1 in Sweden 1 in USA Highly automated screening platforms for both primary and secondary screening Systems from many suppliers Beckman – motorman core systems Agilent (V11) - Biocells The Automation Partnership - Asset RTS HighRes Biosolutions – Microstar systems ThermoFisher – CRS F3 automation systems PAA – Elisa workstations and integrated acoustic dispensing systems Extensive experience and proven track record in drug discovery Technology teams (ASTL, CTT) – role is to evaluate new technologies

12. Proprietary and Confidential © AstraZeneca 2008 FOR INTERNAL USE ONLY Contact information Chris Yochim – SPBD External Relations chris.yochim@astrazeneca.com Iain Comley – Science and Technology Alliances iain.comley@astrazeneca.com Kay Tait – Oncology and Infection SPBD kay.tait@astrazeneca.com Jonathan Wingfield – Cancer Technology Team jonathan.wingfield@astrazeneca.com